Brief: Amneal Announces New Data From Phase 3 Study
07/04/2025 13:48
April 7 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES NEW DATA FROM PHASE 3 STUDY SHOWING SIGNIFICANT IMPROVEMENTS IN SLEEP QUALITY WITH CREXONT® (CARBIDOPA AND LEVODOPA) EXTENDED-RELEASE CAPSULES IN PARKINSON’S DISEASE AMNEAL PHARMACEUTICALS INC - CREXONT IMPROVES PDSS-2 SCORES BY -2.35 Source text: ID:nBw43NLcla Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary